Navigation Links
New Prostate Cancer Drug May Hold Promise
Date:4/7/2009

Researchers apply for large-scale testing after 'very promising' early results,,

TUESDAY, April 7 (HealthDay News) -- A new drug with a radically different way of attacking prostate cancer has done well in an initial trial and is ready for larger-scale testing, researchers report.

One standard treatment for the malignancy is to inhibit the activity of androgens, male hormones such as testosterone that help drive tumor growth. Existing anti-androgens try to "shut down the factory" that produces the hormones, but the new drug blocks the receptors for those androgens on the tumor cells, said Dr. Howard I. Scher, chief of the genitourinary oncology service at Memorial Sloan-Kettering Cancer Center in New York City and co-author of a report to be published online by the journal Science.

"There is a lot of interest in the drug, because the preliminary results are very promising," Scher said.

The report in the journal describes the results of the treatment of 30 men with advanced prostate cancer that was not responding to conventional anti-androgen therapy. After treatment with the drug, there were "sustained declines" in blood levels of prostate specific antigen, a biomarker of tumor growth, in 13 of the 30, or 43 percent, which the report called a "promising" result.

The researchers now have data on 114 men given the drug, Scher said. "It showed not only declines in PSA but also regression of the tumor on scans and also that circulating tumor cell counts, another measure of treatment, converted from unfavorable to favorable in a considerable percentage of patients," he said.

Based on those results, Scher said, an application for a large-scale trial has been submitted to the U.S. Food and Drug Administration by Medivation Inc., a California-based biopharmaceutical company that has licensed the drug, now called MDV3100. The hope is that the trial will lead to FDA approval of the drug for clinical use.

The trial would be international in scope, he said, but the length and size have not been determined.

MDV3100 came out of research done at the University of California, Los Angeles, by Dr. Charles L. Sawyers, a cancer biologist who now is chairman of the human oncology and pathogenesis program at Sloan-Kettering.

"My laboratory was studying why men develop resistance to current anti-androgen drugs," Sawyers said. "We found that resistant tumors have higher levels of androgen receptors. What we showed was that cells, by making more of these receptors, can escape those drugs. Based on that, we developed a cell line that made higher levels of receptors and used that as a screen for compounds that could block the receptors."

Sawyers did the research in collaboration with a group led by Michael Jung, a chemist at UCLA. "We had some ideas about what chemical structures we might need to get such a result," Sawyers said. "His group synthesized a set of compounds, my group screened them, and over the months, we learned what to do. There were a number of chemicals known to bind to a receptor with different affinities, and we made derivatives of them."

That work produced more than one effective receptor blocker. MDV3100 was selected as the most promising.

Though the immediate goal is to get FDA approval for use of the drug in men whose prostate cancers do not respond to existing anti-androgen therapy, the ultimate hope is that it could be used for first-line therapy, Scher and Sawyers said.

"That is a typical scenario," Sawyers said. "First you test it in late-stage patients. If it is effective there, you would want to move it to front-line therapy."

About half of all prostate cancers have the overgrowth of androgen receptors that MDV3100 is designed to attack, Scher noted.

Side effects do not appear to be a problem, Sawyers said. "At high doses, fatigue has been a problem in some men -- higher doses than are needed to get benefit," he said.

More information

The U.S. National Cancer Institute has more on prostate cancer.



SOURCES: Howard I. Scher, M.D., chief, genitourinary oncology service, Memorial Sloan-Kettering Cancer Center, New York City; Charles L. Sawyers, M.D., chairman, human oncology and pathogenesis program, Memorial Sloan-Kettering Cancer Center, New York City; April 9, 2009, Science, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. First biomarker discovered that predicts prostate cancer outcome
3. Frequent Prostate Screens Fail to Improve Aggressive Cancer Diagnoses
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Red wine compound shown to prevent prostate cancer
7. Barbershop Talks Cut Black Mens Prostate Cancer Risk
8. Generic prostate drug helps find high-risk cancers early
9. Finasteride unlikely to induce high grade prostate cancers
10. Shrinkage of prostate led to overestimation of cancer risk in trial
11. Prostate Cancer Awareness Week to Screen Thousands
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Prostate Cancer Drug May Hold Promise
(Date:5/27/2016)... , ... May 27, 2016 , ... With over 60 ... walk, the demand for a sustainable product to aid in the rehabilitation process has ... in the recovery of individuals with hemiplegia due to stroke. , Ekso Bionics has ...
(Date:5/27/2016)... ... ... Beleza Medspa has initiated a new program to assist active ... time that Coolsculpting is being used for for more than just cosmetic purposes. ... the prescribed body-fat standard, measured by the circumference-based tape method. The tape-test is ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of certified ... industries. Aside from its GMP accreditation, Validation Center is also a registered authority ... services and staff. , Validation Center is ISO17025 accredited and only offers its ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, ... respirators, according to court documents and SEC filings. A jury has returned ... v. American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury ...
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For Heroes ... lives in military battle for the country. The nonprofit Hope For Heroes partnered ... programs that empower independence for disabled military veterans, as well as police, firemen, and ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016 MedDay, a ... announces that an oral presentation entitled "High doses of biotin ... trial" will be given by Professor Ayman Tourbah , ... Congress of the European Academy of Neurology (EAN) in ... related disorders 3" will take place on Sunday, 29 May ...
(Date:5/25/2016)... India , May 25, 2016 ... Review, H1 2016"market research report that provides an ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
(Date:5/24/2016)... 24, 2016 Cirujanos holandeses han ... a los médicos a compartir sus mejores prácticas por ... mundial. Profesionales médicos de Europa, África, Asia ... a la aplicación, que combina la transmisión en vivo ... seguro. Educación   "Imagine un médico ...
Breaking Medicine Technology: